8 Apr
2021

Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

The deal struck with Helsinn Group is the latest evidence of the new opportunities for IP monetisation provided by hub-and-spokes life sciences companies

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth